Table 1.
Variable | JIA (N=86) | ERA (N=52) | JPsA (N=34) |
Age (years), mean (SD) | 13.1 (3.1) | 13.7 (2.6) | 12.2 (3.7) |
Male, n (%) | 57 (66.3) | 41 (78.8) | 16 (47.1) |
Race, n (%) | |||
White | 82 (95.3) | 51 (98.1) | 31 (91.2) |
Other* | 4 (4.7) | 1 (1.9) | 3 (8.8) |
Ethnicity, n (%) | |||
Hispanic or Latino | 5 (5.8) | 2 (3.8) | 3 (8.8) |
Caucasian | 67 (77.9) | 42 (80.8) | 25 (73.5) |
Unknown† | 14 (16.3) | 8 (15.4) | 6 (17.6) |
JADAS-27 score, mean (SD) | 15.1 (7.1) | 14.8 (6.7) | 15.5 (7.8) |
Physician global assessment of disease activity (VAS 0–100 mm), mean (SD) | 47.3 (21.1) | 47.2 (20.2) | 47.4 (22.9) |
Parent/patient global assessment of overall well-being (VAS 0–100 mm), mean (SD) | 48.5 (28.3) | 50.0 (27.6) | 46.3 (29.5) |
Childhood Health Assessment Questionnaire–Disability Index, mean (SD) | 0.8 (0.6) | 0.8 (0.6) | 0.8 (0.7) |
Number of joints with active arthritis, mean (SD) | 7.7 (7.5) | 6.2 (3.4) | 10.0 (10.6) |
Number of joints with limited range of motion, mean (SD) | 5.5 (4.7) | 4.9 (3.3) | 6.6 (6.3) |
C-reactive protein standardised value (mg/L), mean (SD) | 18.6 (32.0) | 24.0 (38.8) | 10.4 (14.0) |
Total enthesitis count, mean (SD) | 2.6 (2.5); n=85 | 2.7 (2.2); n=52 | 2.3 (3.0); n=33 |
Total dactylitis count, mean (SD) | 1.0 (2.2); n=82 | 0.4 (1.4); n=48 | 1.8 (2.7); n=34 |
MTX use, n (%) yes | 56 (65.1) | 33 (63.5) | 23 (67.6) |
*Asian and other races.
†ethnicity not reported or unknown.
ERA, enthesitis-related arthritis; JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; TP, treatment period; VAS, visual analogue scale.